CAMBRIDGE, England — August 27, 2025 — Leads & Copy — clock.bio, a rejuvenation biology company, has appointed Dr. Michael Boehler, formerly of BioNTech, as Chief Business Officer. Dr. Boehler will spearhead business development, strategic partnerships, and commercialization efforts to advance clock.bio’s rejuvenation biology platform.
According to Markus Gstöttner, CEO of clock.bio, Dr. Boehler’s experience in BioNTech’s global commercial scale-up and partnership-building abilities makes him well-suited to help translate science into therapies that extend healthspan. Dr. Boehler brings over 20 years of life sciences experience, including roles at BioNTech where he helped build the company’s global commercial organization and contributed to its IPO.
Prior to BioNTech, Dr. Boehler held leadership positions at Takeda, Kite Pharma, and Amgen. clock.bio is developing therapies to reverse aging and extend healthspan, utilizing a platform that decodes the rejuvenation genome through technologies like the geneAge Atlas, imAge (an AI-powered system), and the clinAge Platform.
Dr. Mark Kotter, Founder and Executive Chairman of clock.bio, said Dr. Boehler’s experience will be pivotal in building partnerships to deliver therapies to patients. clock.bio’s initial focus is on topical and nutraceutical applications, with the goal of developing systemic therapies.
Dr. Michael Boehler, Chief Business Officer. Contact information not provided.
Source: clock.bio
